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Several neurodegenerative diseases associated with protein mis-
folding (Alzheimer’s and Parkinson’s disease) exhibit oxidative and
nitrergic stress following initiation of neuroinflammatory path-
ways. Associated nitric oxide (NO)-mediated posttranslational
modifications impact upon protein functions that can exacerbate
pathology. Nonenzymatic and irreversible glycation signaling has
been implicated as an underlying pathway that promotes protein
misfolding, but the direct interactions between both pathways are
poorly understood. Here we investigated the therapeutic potential
of pharmacologically suppressing neuroinflammatory NO signal-
ing during early disease progression of prion-infected mice. Mice
were injected daily with an NO synthase (NOS) inhibitor at early
disease stages, hippocampal gene and protein expression levels of
oxidative and nitrergic stress markers were analyzed, and electro-
physiological characterization of pyramidal CA1 neurons was per-
formed. Increased neuroinflammatory signaling was observed in
mice between 6 and 10 wk postinoculation (w.p.i.) with scrapie
prion protein. Their hippocampi were characterized by enhanced
nitrergic stress associated with a decline in neuronal function by 9
w.p.i. Daily in vivo administration of the NOS inhibitor L-NAME
between 6 and 9 w.p.i. at 20 mg/kg prevented the functional de-
generation of hippocampal neurons in prion-diseased mice. We
further found that this intervention in diseased mice reduced
3-nitrotyrosination of triose-phosphate isomerase, an enzyme in-
volved in the formation of disease-associated glycation. Further-
more, L-NAME application led to a reduced expression of the
receptor for advanced glycation end-products and the diminished
accumulation of hippocampal prion misfolding. Our data suggest
that suppressing neuroinflammatory NO signaling slows func-
tional neurodegeneration and reduces nitrergic and glycation-
associated cellular stress.
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Diseases associated with old age, including Alzheimer’s dis-ease (AD) and other forms of dementia, are increasing in
prevalence, and although symptomatic treatments exist, no cure
to prevent the disease progression has yet been described.
Neurodegenerative diseases associated with the accumulation of
misfolding proteins including AD, Parkinson’s disease (PD), and
various forms of prion disease share many common features such
as up-regulation of neuroinflammatory signaling (1). In particular,
such signaling can compromise synaptic plasticity (2) in early de-
generation representing an initiation phase for dysfunction. It is
well established that cellular stress signaling in neurodegenerative
diseases is associated with aberrantly elevated levels of nitric oxide
(NO) and activation of oxidative/nitrergic stress pathways (3–5).
NO has both physiological and pathological roles in the nervous
system where it is synthesized by NO synthases (neuronal NOS
[nNOS], inducible NOS [iNOS], and endothelial NOS [eNOS]).
Excessive NO production reported in prion disease, AD, and PD
is inducing aberrant posttranslational protein modifications and
uncontrolled neurotoxic nitrergic signaling (6–9). Protein cysteine
residues can be directly and reversibly S-nitrosylated by NO (9)
which can lead to protein dysfunction to facilitate disease pro-
gression (10, 11). NO also reacts with free radicals such as su-
peroxide anion O2
•− resulting in the generation of peroxynitrite
(ONOO−) which accumulatively induces protein nitrotyrosination,
the irreversible chemical addition of a nitro group to protein ty-
rosine residues generating 3-nitrotyrosine (3-NT), which can result
in a loss of physiological protein function (12). Therefore, pre-
venting disease-relevant, in particular, iNOS-mediated NO gen-
eration presents a strong and promising therapeutic target across
many neurological diseases (13–15).
In neurodegenerative diseases, oxidative and nitrergic stress is
believed to be an initiator of many pathological pathways further
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augmenting underlying neurodegeneration (16–18). For exam-
ple, 3-NT of β-amyloid (Aβ) oligomers presents a direct pathway
for increasing oligomer stability and toxicity (12, 19). Interest-
ingly, Aβ42 oligomerization also plays a key role by promoting
nitrergic stress, i.e., inducing 3-NT of numerous neuronal pro-
teins (20). One targeted protein is the enzyme triose-phosphate
isomerase (TPI) which regulates the glycolytic flow by inter-
converting dihydroxyacetone phosphate (DHAP) and glyceral-
dehyde 3-phosphate (GAP). The nitrergic posttranslational
modification of TPI induced by the Aβ42 peptide reduces its
enzymatic activity (21) leading to a shift of balance of the me-
tabolites toward DHAP formation. Subsequently, DHAP trans-
forms spontaneously into the cytotoxic metabolic by-product
methylglyoxal (22, 23). A nitrooxidative environment favors high
levels of 3-nitrotyrosinated TPI in AD patients (21), and as a result,
inhibition of this enzyme leads to nonenzymatic methylglyoxal-
mediated generation of protein glycation (21) and formation of
advanced glycation end-products (AGE).
The production of AGE is irreversible and resulting glycated
proteins have a propensity to aggregate (24) while exhibiting re-
sistance to protease degradation. Notably, protein glycation is a
marker of aging, and it promotes inflammation via the overpro-
duction of intracellular reactive oxygen species (ROS) in addition
to impairing proteasomal activities. The resulting AGE-mediated
induction of oxidative stress thereby leads to augmented oxidative
damage in the brain presenting a positive feedback loop of neu-
rotoxic pathways in different protein misfolding diseases (25, 26).
In AD, the aggregation and deposition of AGEs have been ob-
served in tau positive intracellular aggregates and Aβ plaques (27,
28) with the polymerization of Aβ being significantly accelerated
by AGE-mediated protein cross-linking (29). Glycation at specific
residues causes a profound impact on the ability to form amyloid
fibrils (30, 31) confirming a contributing role of this modification
in aggregation. AGEs are principally recognized by the receptor
for AGE (RAGE) that belongs to the immunoglobulin gene su-
perfamily. RAGE is found on the surface of numerous cells types
including microglia, monocytes, astrocytes, neurons, and endo-
thelial cells (32). RAGE activation results in the stimulation of
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
(33), an enzyme that produces superoxide radicals. It also induces
the production of cytokines via NF-κB expression, followed by up-
regulation of inflammatory pathways (32). Importantly, AGE-
formation and RAGE expression are increased in brains from
Creutzfeldt Jakob disease (CJD) patients and are associated with
enhanced oxidative and nitrergic stress (34, 35) suggesting the
possibility that AGE-mediated modifications might, in part, play a
role in the accumulation of the aberrant prion protein.
In this study, we investigated neurodegeneration induced by
prion misfolding to assess the role of nitrergic stress caused by
excess neuroinflammatory production of NO. We established
that the decline of hippocampal CA1 pyramidal neuronal func-
tion is associated with increased nitrergic stress and reduced
levels of antioxidants and that prolonged in vivo treatment with
an NOS inhibitor reduced prion protein aggregation and di-
minished aspects of neurodegenerative signaling such as neuro-
nal and synaptic dysfunction. We further found that blocking NO
signaling prevented nitrotyrosination of TPI and RAGE up-
regulation.
Materials and Methods
Mice and Prion Inoculation. Hemizygous Tg37 mice that overexpress the
cellular mouse prion protein (PrPC) have been used as described previously
(36). Mice were fed ad libitum with a standard mouse chow. Tg37 mice aged
3 wk were inoculated by intracerebral injection into the right parietal lobe
with 1% brain homogenate of Rocky Mountain Laboratory (RML) misfolded
prion protein (PrPSc) (36). Control mice received 1% normal brain homoge-
nate (NBH), and hippocampi and cortices of both groups were used for
analyses.
Animal Drug Treatment. RML-inoculated mice were treated (i.p.) with vehicle
(5% glucose [control]) or N(ω)-nitro-L-arginine methyl ester (L-NAME,
20 mg/kg) daily from 6 wk postinoculation (w.p.i.) for 3 wk. This dosage
provides an ∼70% inhibition of lipopolysaccharide-induced NOx generation
(via iNOS induction) in mice with an ED50 for L-NAME of 5 mg/kg (37). The
presence of the L-NAME metabolite and active inhibitor of NOS in the brain,
L-NOARG (38), was confirmed by high-performance liquid chromatography
(HPLC; SI Appendix) at a concentration of 11.8 ± 1.1 nM/g tissue (n = 8 mice).
Western Blotting. Mouse hippocampi were dissected into ice-cold phosphate-
buffered saline (PBS) containing protease inhibitors and phosphatase in-
hibitors (Complete, Roche Diagnostics), and samples were flash-frozen in
liquid nitrogen until further analysis. All the following procedures were then
performed at 4 °C. Frozen tissue was homogenized in ice-cold RIPA buffer
(20 mM Tris [pH 7.4], 150 mM NaCl, 3 mM EDTA, and 1% Nonidet P-40) and
1× protease inhibitor mixture with a tissue homogenizer (IKA T10 basic
ULTRA-TURRAX). Total protein concentration was measured by the Bradford
method (BioRad Protein assay kit). Primary antibody details are shown in
SI Appendix.
Immunocytochemistry. Mice were anesthetized with 3% isofluorane (2 L/min
O2) and transcardially perfused with 20 mL of ice-cold PBS, followed by
20 mL of ice-cold 4% PFA. Following fixation, brains were immediately re-
moved and further fixed overnight in 4% PFA at 4 °C. Brains were processed
in paraffin wax and sliced at 5 μM using a microtome. Following antigen
retrieval, sections were washed in TBS + 0.1% triton X-100 and blocked for
2 h at RT in TBS, 0.1% triton X-100, 10% goat serum, and 5% BSA. Following
three washes, slices were mounted in Vectorshield hardset mounting me-
dium with/without DAPI (Santa Cruz). Antibody and cell count analysis de-
tails are shown in SI Appendix. All images were taken using a Zeiss LSM 510
META NLO microscope with ZEN 2009 software (Zeiss).
NADPH-Diaphorase Assay.Micewere anesthetized and transcardially perfused
with PBS then 4% PFA. The brain was removed and fixed for 24 h in PFA
before being embedded in paraffin. Five-μm sections were cut and depar-
affinized before being incubated in a mixture of 2.5 mg nitroblue tetrazo-
lium, 10 mg β-NADPH, and 0.2% Triton X-100 in 10 mL of 0.05 M Tris buffer
for 30 min at 37 °C. The reaction was terminated with 0.05 M Tris buffer
washes.
qRT-PCR. Total RNA was extracted from isolated hippocampal tissue using
RNeasy mini kit (Qiagen) and treated with deoxyribonuclease 1. For each
tissue, 1 μg of total RNA was reverse transcribed using an iScript cDNA
synthesis kit according to the manufacturer’s instructions (BioRad). Real-time
PCR reactions were performed using 25 to 100 ng of template cDNA per
reaction and Taqman gene expression “assay on demand” assays. The target
primer/probes are presented in SI Appendix. Relative mRNA expression in
each region was determined by normalizing to the average amount of
hippocampus or cortex from NBH mice using the ΔΔCT method.
Electrophysiology. Brain slices were prepared from animals killed by cervical
dislocation. Whole-cell patch recordings were made from visually identified
CA1 neurons in acute brain slices (300 μm thick) of the hippocampus as
described previously (39, 40). Data were recorded using a Multiclamp 700B
amplifier (Molecular Devices). Stimulation, data acquisition, and analysis
were performed using pClamp 10.4 and Clampfit 10.4 (Molecular Devices).
An artificial cerebrospinal fluid (aCSF) was used for slice incubation and
perfusion during recordings. A low-sodium aCSF was used during prepara-
tion of slices. Synaptic stimulation at the Schaffer collateral was achieved
using an isolated stimulator via a bipolar platinum electrode. Solutions and
protocols are detailed in SI Appendix.
Ultrahigh-Performance Liquid Chromatography-Tandem Mass Spectroscopy.
Mass spectrometry studies were performed by Metabolon as described
previously (8). Samples were prepared using the automated MicroLab STAR
system (Hamilton Company). To remove protein, dissociate small molecules
bound to protein or trapped in the precipitated protein matrix, and recover
chemically diverse metabolites, proteins were precipitated with methanol
under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by
centrifugation; see SI Appendix for further details.
Statistical Analysis. Results are expressed as the means ± SEM. Statistical
comparisons were made by one-way analysis of variance (ANOVA) with
Newman–Keuls posteriori analysis, two-way ANOVA with Bonferroni’s multiple
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comparisons test, Kolmogorov–Smirnov test for nonparametric data distribu-
tions, or unpaired Student’s t test, as appropriate. All datasets passed the
normality testing using the Shapiro–Wilk test. A P value smaller than 0.05 was
considered as significant. All statistical tests were performed using GraphPad
Prism v9 software.
Study Approval. All animal work conformed to the United Kingdom Home
Office regulations. All procedures were conducted under a Home Office
project license awarded to J.R.S. under the Animals (Scientific Procedures)
Act 1986.
Results
Prion-Diseased Mice Show Signs of Neuroinflammation prior to
Neuronal Dysfunction. Previously, we have found that in the hip-
pocampus and cortex of prion-infected mice the neuronal metab-
olism, not only related to the NO signaling cascade, is aberrantly
regulated at 10 w.p.i. (8). At this advanced time point we found
evidence for numerous pathological markers such as high levels of
misfolded prion protein (PrPSc) in the hippocampus and cortex,
enhanced glial fibrillary acidic protein (GFAP) expression associ-
ated with nitrergic and oxidative stress, and hippocampal neuronal
loss as well as learning and memory deficits (40). However, as the
disease is highly progressed by 10 w.p.i., we investigated in this
study disease-relevant pathways which may present a potential
target for disease rescue at earlier time points. We examined the
contributions of neuroinflammatory and oxidative stress-related
signaling in prion-infected mice (RML) at a time point prior to
onset of reported disease symptoms (at 6 w.p.i.), as well as ad-
vanced disease stages (at 9 to 10 w.p.i.). We first tested gene ex-
pression for the inflammatory suppressor of NF-κB signaling, Iκbα,
and found it to be down-regulated at 6 w.p.i. compared to NBH
Fig. 1. Neuroinflammation is enhanced early in prion disease. mRNA levels were determined at 6 and 10 w.p.i. in control (NBH) and prion-infected (RML)
mice for the following genes: (A) Iκbα, (B) NCF1, (C) PGC-1α, (D) STIP1, and (E) Nos2. (F) NADPH diaphorase staining of prion-inoculated brains (RML) at 6 to 12
w.p.i. shows enhanced signals in disease detectable after 6 w.p.i. with strong signals in the CA1 and at later time points spreading across the whole hip-
pocampus. (G) (Left) Immunocytochemistry images show representative GFAP and DAPI staining in the hippocampus of NBH and RML mice at 10 w.p.i. and
(Right) GFAP signals presented as absolute area. (Scale bar: 50 μm.) Data are presented as mean ± SEM, n = 4 NBH and n = 7 RML mice, two-way ANOVA (A–E)
and unpaired Student’s t test (G), *P < 0.05, **P < 0.01, ***P < 0.001.
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mice (P = 0.038, two-way ANOVA, n = 4 mice each; Fig. 1A).
RNA expression for the peroxisome proliferator-activated receptor-
gamma coactivator, PGC-1α, which controls the expression of
genes related to the generation of ROS and prevents oxidative
stress by reducing the production of ROS (41), is also down-
regulated at this early stage of disease (P = 0.0015, two-way
ANOVA, n = 4 mice each; Fig. 1C), as is the prion-interacting
protein stress-inducible phosphoprotein 1, STIP1 (42) (P = 0.0013,
two-way ANOVA, n = 4 mice each; Fig. 1D). At 10 w.p.i. we
found a strong increase in mRNA levels for Iκbα (P = 0.012) as
well as NCF1 (P < 0.0001), one of the components of NADPH
oxidase (p47-phox [Fig. 1 A and B], n = 4 mice each). Further-
more, PGC-1α (P < 0.0001, two-way ANOVA) and STIP1 (P =
0.0047, two-way ANOVA) mRNA levels remain reduced at this
later disease stage (Fig. 1 C and D). Importantly, Nos2 mRNA
(iNOS) is increased at 10 w.p.i. (P = 0.0266, two-way ANOVA;
Fig. 1E) with Nos1 (nNOS) and Nos3 (eNOS) mRNA levels being
strongly reduced at 6 and 10 w.p.i. (SI Appendix, Fig. S1). The
enhanced iNOS activity is likely a result of activated astroglia
signaling which we further illustrated using the NADPH diapho-
rase assay at 6 to 12 w.p.i. (Fig. 1F). We have previously shown
that NBH mice lack any significant NADPH diaphorase signals at
10 w.p.i. (8). These data illustrate a strong increase of NOS
(NADPH activity) from 8 w.p.i. onward in RML mice with signals
reminiscent of activated astroglia in the CA1 region spreading to
the whole hippocampus at 10 and 12 w.p.i. Further characteristics
for up-regulated astroglia were detected by immunostaining for
GFAP which showed a significantly stronger expression at 10 w.p.i.
in RML hippocampi (P = 0.045, Student’s t test; Fig. 1G). Alto-
gether, our data indicate that an early onset neuroinflammatory
contribution to prion disease is detectable from 8 wk onward.
Thus, our approach to start targeting NO signaling will focus on
time points following 6 w.p.i. onward.
Reducing Nitrergic Stress Prevents Neuronal and Synaptic Dysfunction
in Neurodegeneration. We next asked whether interference with
neuroinflammatory NO signaling prior to detectable prion mis-
folding might alleviate some of the neuronal symptoms reported in
the disease. In order to address this question, subsequent studies
specifically focused on RML mice and the effects of treatment
since we did not find any indications for aberrant nitrergic sig-
naling in NBH controls (Fig. 1). We quantified the electrophysi-
ological phenotypes of CA1 pyramidal neurons and their Schaffer
collateral-mediated synaptic inputs as a read-out of neuronal
health in RML prion-infected mice treated with the NOS inhibi-
tor, L-NAME, daily from 6 w.p.i. in comparison to age-matched
vehicle-treated RML (all 7 and 9 w.p.i.) and NBH controls (7
w.p.i.). These time points were chosen to study the effects of NOS
manipulation based on data presented in Fig. 1 at which we expect
pathological neuroinflammation to become dominant. Fig. 2A
shows representative Schaffer collateral-evoked excitatory post-
synaptic currents (eEPSC) in pyramidal CA1 neurons in RML
mice at 7 and 9 w.p.i. following stimulation by a 30-Hz train. The
recordings illustrate a vast deterioration in neuronal function by 9
w.p.i. Mean initial eEPSC amplitudes (arrow) from NBH, vehicle-
(RML), or L-NAME–treated RML mice are summarized in
Fig. 2B showing a strong reduction at 9 wk. Following 3 wk of daily
treatment with L-NAME, the decline in mean initial current
amplitudes was prevented (NBH vs. RML 9 w.p.i., P < 0.0001,
one-way ANOVA; Fig. 2B). Cumulative postsynaptic current
analysis, a measure to estimate available vesicle pool sizes based
on the cumulative eEPSC amplitude plots, revealed a larger ve-
sicular pool size at 9 w.p.i. following L-NAME treatment (P =
0.043, two-way ANOVA; SI Appendix, Fig. S2) suggesting a re-
duced deterioration of synapse function following treatment. An
important regulatory mechanism for synaptic vesicular release is
the control of release probabilities. As a measure to determine
the initial synaptic release probabilities, we assessed paired-pulse
ratios (PPR, eEPSC2/eEPSC1 amplitude) at 33-ms interspike in-
tervals of Schaffer collateral-stimulated eEPSCs in treated and
untreated RML mice. PPR values of synaptic responses in hip-
pocampi from untreated mice revealed a significant increase at 9
w.p.i. indicating a reduction in release probability over time (P =
0.0145, two-way ANOVA; SI Appendix, Fig. S2). L-NAME
treatment, however, suppressed this increase in PPRs, which
suggests that NOS inhibition prevents different aspects of synapse
dysfunction. A further assessment criterion of neuronal health
is the ability of synapses to spontaneously release vesicles. These
spontaneous or miniature EPSCs (mEPSC) provide important
signals for physiological neuronal homeostatic signaling (43).
Consistent with above data, we found that mEPSC amplitudes
were increased following 3 wk of L-NAME treatment compared
to vehicle treatment (RML 9 w.p.i. vs. RML 9 w.p.i. + L-NAME,
P = 0.0015) and compared to 1 wk of L-NAME treatment (RML 7
w.p.i. + L-NAME vs. RML 9 w.p.i. + L-NAME, P = 0.0004, one-
way ANOVA; Fig. 2 C and D). Furthermore, spontaneous firing
frequencies were reduced at 9 w.p.i. compared to NBH (P =
0.0146) and RML at 7 w.p.i. (P = 0.0007; Fig. 2 C and D), with
L-NAME treatment increasing firing rates at both time points
relative to vehicle treatment (7 w.p.i., P = 0.0068; 9 w.p.i., P =
0.0024, one-way ANOVA). Analyzing the relative cumulative
distributions of mEPSC amplitudes and interspike intervals (ISI)
of spontaneous release events revealed a strong leftward shift
in amplitudes and rightward shift in ISI values in diseased mice at
9 w.p.i. compared to 7 w.p.i. (SI Appendix, Fig. S2; amplitudes, P <
0.0001, D = 0.571; ISI, P < 0.0001, D = 0.738; Kolmogorov–Smirnov
test, 9 vs. 7 w.p.i.). A protective effect of L-NAME treatment was
observed at 9 w.p.i. (SI Appendix, Fig. S2; amplitudes, P < 0.0001,
D = 0.571; ISI, P < 0.0001, D = 0.683; Kolmogorov–Smirnov test, 9
w.p.i. vs. 9 w.p.i. + L-NAME treatment).
We next assessed neuronal function by measuring the ability of
CA1 pyramidal neurons to generate current-evoked action po-
tentials (AP) and characterized the underlying whole-cell po-
tassium and sodium currents. Both ion channel function and AP
propagation play crucial roles in regulating neuronal perfor-
mance and allow the neurons to sustain reliable information
transmission. AP parameters such as half-width and amplitude
are main characteristics, both predominately determined by po-
tassium and sodium channel activities, respectively. L-NAME
treatment averted the increase in AP half-width at 9 w.p.i. (NBH
vs. RML 9 w.p.i., P = 0.0174; RML 9 w.p.i. vs. RML 9 w.p.i. +
L-NAME, P = 0.0008, one-way ANOVA; Fig. 3 A and B) indi-
cating a disease-linked reduction in potassium currents, pre-
vented by NOS inhibition. AP amplitudes were reduced at
9 w.p.i. (NBH vs. RML 9 w.p.i., P = 0.0311; RML 7 w.p.i. vs.
9 w.p.i., P = 0.0262, one-way ANOVA) and increased at 9 w.p.i.
following L-NAME treatment (Fig. 3 A and B; RML 9 w.p.i. vs.
RML 9 w.p.i. + L-NAME, P = 0.0336, one-way ANOVA),
suggesting an involvement of sodium channel activities which
provide the predominant driving force for the depolarization
during an AP (44). A change of AP waveforms becomes more
apparent in the generated phase plots of APs from NBH, RML,
and RML + L-NAME–treated mice. The phase plots show that
the maximal upstroke (dV/dt) values of an AP, where the
inflowing sodium current is highest, has increased drastically fol-
lowing L-NAME treatment compared to AP upstroke values in
RML mice (Fig. 3C) which would be indicative of smaller sodium
currents and directly translates into smaller AP amplitudes (44).
We next assessed both voltage-gated potassium and sodium
currents directly by voltage clamp. Current–voltage (IV) rela-
tionships showed a strong decline of outward potassium currents
(Fig. 3 D and E; NBH vs. RML 9 w.p.i., P < 0.05 at +40 mV and
+50 mV, two-way ANOVA) and inward sodium currents at 9
w.p.i. in RML mice (Fig. 3F; NBH vs. RML 9 w.p.i., P < 0.05
between −110 and −10 mV, two-way ANOVA), in agreement
with the observed changes in AP parameters, with L-NAME
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treatment preventing the decline of both currents at 9 w.p.i.
(potassium current, RML 9 w.p.i. vs. RML 9 w.p.i. + L-NAME,
P < 0.05 between 0 and +50 mV; sodium current, RML 9 w.p.i.
vs. RML 9 w.p.i. + L-NAME, P < 0.05 between −110
and −30 mV, two-way ANOVA). The data on neuronal physi-
ology were supported by measurements of neuronal proteins
levels involved in synaptic function and neuronal fidelity. Protein
levels of several synaptic markers, including MUNC 18, SNAP-
25, and complexin 1/2, were reduced with others showing strong
tendencies of lower expression (synaptophysin, synaptobrevin,
and synapsin) at 9 w.p.i. (SI Appendix, Fig. S3). Protein expres-
sion of the voltage-gated potassium channel Kv3.1, one of the
main conductances contributing to the presented IV relation-
ships in Fig. 3D and determinants of AP half-width, declined at 9
w.p.i. Altogether, the data illustrate the broad neuronal dys-
function at late disease stages and the potent effects of L-NAME
treatment to prevent several aspects of the dysfunction via sup-
pression of excessive NO signaling in vivo.
Protein 3-Nitrotyrosination Is Driven by Oxidative Stress and Enhances
Protein Glycation in Prion Disease. Protein 3-nitrotyrosination is
characteristic of protein-misfolding neurodegeneration (22, 45).
The 3-NT occurs under conditions of oxidative stress and aberrant
nitrergic activity. We confirmed a decreased ratio of reduced to
oxidized glutathione (GSH/GSSG) in prion-diseased mice at 9
w.p.i. (P = 0.0039, control NBH vs. RML mice, Student’s t test;
Fig. 4A) providing evidence for enhanced oxidative stress as one
hallmark of the disease and confirming previously reported in-
creases in oxidative stress levels in prion-diseased mice (8). To-
gether with the enhanced levels of nitrergic stress associated with
augmented expression levels of iNOS mRNA (Fig. 1), we found
total amounts of 3-nitrotyrosinated proteins to be greater than
fivefold elevated in prion-infected mice compared to NBH con-
trols at 9 w.p.i. (P = 0.0005, control NBH vs. RML, one-way
ANOVA; Fig. 4B). Importantly, we could not detect these ele-
vated levels of 3-NT following treatment with L-NAME (P =
0.0005, RML + L-NAME vs. RML, one-way ANOVA; Fig. 4B).
Fig. 2. Decline in synaptic strength is prevented by NOS antagonism. (A) Representative eEPSC trains recorded at 30 Hz for 10 s in the CA1 pyramidal neurons
from a RML mouse at 7 w.p.i. and RML mouse at 9 w.p.i. (B) Initial eEPSC amplitudes for NBH (gray) and vehicle-treated (black) and L-NAME–treated RML (red)
mice at both time points. (C) Raw traces showing spontaneous release events for NBH and RML mice at indicated time points. mEPSC (D) amplitudes and (E)
frequencies show disease-dependent decline (black) in RML mice. L-NAME treatment prevented the reduction in mEPSC amplitudes and frequencies (red).
Data are presented as mean ± SEM, n = 4 NBH, n = 9 RML and n = 6 RML + L-NAME–treated mice with n = 4 to 10 neurons per mouse, one-way ANOVA, *P <
0.05, **P < 0.01, ***P < 0.0001.
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Fig. 3. Neuronal function is protected by NOS antagonism. (A) Representative current-evoked AP recordings. (B) AP half-width and amplitudes were an-
alyzed at 7 and 9 w.p.i. for NBH (gray), vehicle-treated (black), and L-NAME–treated RML (red) mice. (C) Phase plots for averaged APs from NBH, RML, and
RML + L-NAME–treated mice. Note the strongly reduced upstroke values (dV/dt) and amplitudes in RML mice which were recovered following L-NAME
treatment. (D) Representative recordings of voltage-gated potassium currents at 7 and 9 w.p.i. in RML mice. (E) IV relationships at 7 and 9 w.p.i. for NBH, RML,
and RML + L-NAME–treated mice. Treatment prevented the decline in voltage-gated potassium currents at 9 w.p.i. (red). (Right) Mean currents at +50 mV. (F)
Voltage-gated sodium currents decline at 9 w.p.i. in RML mice with L-NAME treatment (red) preventing the reduction in currents at 9 w.p.i. (representative
recordings at 9 w.p.i.). Data are presented as mean ± SEM, n = 4 NBH, n = 9 RML and n = 6 RML + L-NAME–treated mice with n = 4 to 6 neurons per mouse,
one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Both AD and CJD are associated with neurotoxic glycation
signaling as well as a strong presence of AGEs (22, 23, 35). The
predominant neuronal precursor to induce protein glycation is
DHAP which spontaneously forms methylglyoxal, a strong gly-
cating agent (46). We have measured DHAP by mass spectrom-
etry and found levels to be approximately twofold increased (P =
0.0027, Student’s t test; Fig. 4C) in the hippocampus of prion-
infected mice. As TPI is the upstream enzyme in the cascade to
interconvert DHAP into GAP, a reduction of its enzymatic activity
would be responsible for the observed accumulation of DHAP. It
has been previously reported that mutations of TPI carrying the
tyrosine substitutions Y165F and Y209F, both of which are lo-
cated at the catalytic center, render this enzyme inefficient when
expressed in human neuroblastoma cells thereby shifting the bal-
ance between GAP and DHAP toward the latter and reducing cell
viability (23). Based on these findings, we tested whether we could
detect a nitrergic posttranslational modification of TPI in prion-
diseased mice that would ultimately be responsible for an accu-
mulation of DHAP. Indeed, when performing immunoblotting for
3-nitrotyrosination after having immunoprecipitated TPI, we
detected an increase of 3-NT TPI protein levels in diseased mice
(Fig. 4D; P = 0.033, one-way ANOVA, RML vs. NBH). Impor-
tantly, treatment with L-NAME prevented the increase in 3-NT
TPI resulting in levels similar to NBH controls (Fig. 4D; P = 0.484,
one-way ANOVA, NBH vs. RML + L-NAME). Total amounts of
TPI protein were unchanged (Fig. 4F; P = 0.163, one-way
ANOVA). The production of AGE following TPI nitro-
tyrosination and DHAP accumulation is directly linked to the
activation of the receptor for AGE (RAGE), and the expres-
sion of RAGE reflects evidence for AGE signaling (47). To test
whether we could corroborate enhanced AGE signaling in prion
mice we examined RAGE expression and found that prion-
diseased mice exhibited markedly enhanced levels of RAGE
(Fig. 4E; P = 0.0074, one-way ANOVA). We tested the effects of
NOS inhibition on RAGE expression and found that treatment
with L-NAME ameliorated these increases (Fig. 4E; P = 0.0243,
one-way ANOVA; note the lower band represents actin) provid-
ing strong evidence for the NO-mediated 3-NT/TPI/DHAP/
RAGE signaling cascade in prion disease which signifies a disease-
associated neurotoxic pathway.
Fig. 4. NOS inhibition reduces protein 3-nitrotyrosination and glycation signaling. (A) The ratio of reduced/oxidized glutathione is diminished in hippo-
campal tissue from RML mice at 10 w.p.i.. (B) Levels of 3-NT proteins are enhanced in RML and reduced following L-NAME treatment of RML mice. (C) DHAP
levels are increased in the hippocampus of RML mice. (D) The 3-NT formation of triose-phosphate isomerase (TPI) is increased in RML mice and reduced to
control NBH levels following L-NAME treatment of RML mice. (E) RAGE levels (upper band; lower band represents actin) are enhanced in RML hippocampi. (F)
Total TPI levels are not affected by prion disease or treatment. Data are presented as mean ± SEM, n = 6 NBH, n = 9 RML mice (A and C) and n = 3 mice each in
B and D–F. Unpaired Student’s t test, **P < 0.01 (A and C), one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001 (B and D–F)
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Nitric Oxide and Glycation Signaling Impact on Prion Misfolding. The
pathological scrapie form of the prion protein is heavily glycated
resulting in mainly Ne-(carboxymethyl)lysines at up to eight ly-
sine residues, whereas PrPC does not contain glycated amino
acids (48, 49). It has been shown that monoglycation or digly-
cation affects the molecular weight of the prion protein resulting
in multiple bands following immunoblotting. We thus tested for
expression of prion protein in hippocampal tissues. Interestingly,
we noticed the occurrence of bands above the expected PrPc
molecular weight (∼36 kDa) in hippocampal samples of RML
mice at 9 w.p.i. detected using the ICSM35 antibody raised to
specifically recognize β-sheet–rich structures within prion pro-
teins (50) (Fig. 5A). These higher-weight bands might therefore
reflect glycated and β-sheet–enriched prion protein.
We next assessed hippocampal tissue by immunocytochemistry
and stained for prion protein to investigate the localization of the
misfolded protein in NBH and RML mice with and without
L-NAME treatment. In order to specifically visualize β-sheet–rich
PrPSc that is prerequisite for prion aggregation we immunostained
samples using the ICSM35 antibody (50). We detected ICSM35
staining almost exclusively in the cytosol of subiculum neurons in
RML mice reminiscent of possible protein aggregates formed
within the cytosol (49) (Fig. 5 B and C). Subiculum areas from
NBH mice did not show any labeling in neurons (Fig. 5B)
confirming PrPSc-specific detection in RML mice. Counting of
ICSM35-positive (PrPSc) cells in the hippocampus revealed larger
proportions of cells in RML mice compared to RML mice re-
ceiving L-NAME treatment, suggesting a reduction in the ex-
pression of prion protein misfolding (Fig. 5 B and C; RML, 38.8 ±
4.1% [n = 5 mice]; RML + L-NAME, 23.4 ± 2.7% [n = 3 mice],
P = 0.0346, Student’s t test; total cell number from both groups,
679). These data therefore indicate that reducing nitrergic stress
could slow down the progression of protein misfolding and/or
aggregation.
Quantification of total cell numbers (DAPI-positive nuclei)
within the CA1 region revealed a significant reduction in RML
hippocampi at 9 w.p.i. compared to NBH and L-NAME–treated
RML mice (Fig. 5 B and D; DAPI count per μm2, NBH, 0.0064 ±
0.001 [n = 3 mice]; RML, 0.0029 ± 0.0005 [n = 5 mice], P =
0.0397; RML + L-NAME, 0.0059 ± 0.0007 [n = 3 mice], one-
way ANOVA; representative images of DAPI-labeled tissues).
We further confirmed that the absolute numbers of neurons in
the CA1 region of hippocampus of L-NAME–treated mice was
similar to control NBH hippocampi, whereas vehicle-treated
RML mice showed a significant reduction in neuron numbers
(Fig. 5 B and E; NeuN-positive cells per μm2, NBH, 0.0021 ±
0.0001 [n = 3 mice]; RML, 0.0007 ± 0.0001 [n = 5 mice], P =
0.0324; RML + L-NAME, 0.0013 ± 0.0003 [n = 3 mice], one-
way ANOVA; representative images of NeuN-labeled tissues).
These data suggest that L-NAME treatment results in a reduc-
tion of neuronal loss consistent with the L-NAME–mediated
prevention of the decline in neuronal function at this time point
of disease (Figs. 2 and 3).
Previously, we reported that the metabolome of the hippo-
campus as well as the cortex is altered in prion disease at 10
w.p.i. (8). Furthermore, diseased mice exhibit behavioral defi-
ciencies in burrowing activity at 9 w.p.i. (36), a behavior associ-
ated with hippocampal but also cortical dysfunction (51). In
parallel to the hippocampal increases in DHAP levels, we also
confirmed enhanced levels of DHAP in the cortex of RML mice
(scaled intensity, NBH, 0.81 ± 0.07, n = 8; RML, 1.07 ± 0.07, n =
8; P = 0.023, Student’s t test; SI Appendix, Fig. S4B) suggesting a
similar up-regulated glycation signaling. To test if we can detect
potential signs of prion misfolding in the cortex as well and
beneficial effects of L-NAME treatment in cortical regions at 9
w.p.i., we assessed cortical tissues for misfolded prion protein by
immunocytochemistry (ICSM35). We found that in the cortex
from RML mice, prion protein-positive signals exhibit clusters
within the cytosol showing typical punctate localizations as seen
in the immunocytochemistry data in the hippocampus reflecting
a misfolding protein which was absent in tissue from NBH mice
(SI Appendix, Fig. S4B). The number of cells exhibiting such
PrPSc clusters in RML samples was significantly lower following
L-NAME treatment suggesting fewer β-sheet–rich prion protein
levels (RML, 95.0 ± 2.2% [n = 5 mice]; RML + L-NAME,
24.2 ± 5.1% [n = 3 mice], P < 0.0001, Student’s t test; total cell
number, 1,892; SI Appendix, Fig. S4C). Importantly, assessing the
total number of cortical neurons showed that L-NAME treat-
ment prevented the reduction in cell loss in disease (cells per
μm2, NBH, 0.0022 ± 0.0002 [n = 3 mice]; RML, 0.0014 ± 0.00006
[n = 5 mice], P = 0.0119 vs. NBH; RML + L-NAME, 0.0018 ±
0.00004 [n = 3 mice], one-way ANOVA; SI Appendix, Fig. S4D).
Together, our data provide evidence that in vivo NOS inhibition
for 3 wk can reduce the amount of prion protein misfolding which
positively impacts on neuronal health. We propose that nitrergic
stress exerts its effects via posttranslational 3-nitrotyrosination and
associated inhibition of TPI activity leading to an accumulation of
glycated proteins. The resulting generation of advanced glycation
end-products may impact on prion protein misfolding as AGE-
assisted conversion of PrPC into PrPSc also reported for
α-synuclein (25, 26) or the Aβ protein (30).
Discussion
This study was set out to investigate the role of nitrergic stress in
the development of protein misfolding neuropathology using
prion-mediated neurodegeneration as a well-established disease
model system. We show that prion disease is characterized by a
range of dysfunctional pathways involving oxidative stress and
neuroinflammatory nitrergic signaling as well as activation of the
glycation-AGE signaling cascade. Importantly, we also show that
suppressing cytotoxic NO levels throughout early disease stages
can diminish the progression of the neuronal dysfunction. This
was revealed by a sustained synaptic and neuronal function,
prevention of excess glycation signaling, and the reduced gen-
eration of misfolded prion protein in the hippocampus and
cortex of infected animals following NOS inhibition. Although
NO signaling plays an important role in physiological neuronal
function including regulation of ion channel activities (39, 52, 53)
or aspects of neurotransmission (54, 55), NO dysregulation and
nitrergic stress have long been associated with numerous neu-
rodegenerative diseases (3, 9, 56). Its main disease-relevant neu-
rotoxic signaling involves excessive posttranslational protein
modifications, such as S-nitrosylation and 3-nitrotyrosination. For
instance, it has been shown in various systems that S-nitrosylation
of synaptic proteins such as AMPA receptors (57), syntaxin (58),
complexin (59), stargazin (60), or dynamin (61) can modify their
functions (for review, see ref. 4). Several studies have confirmed
that suppressing excess NO production might be beneficial under
various conditions of neuroinflammation which is a major hallmark
of protein misfolding diseases. As such, targeting NO signaling
presents an attractive approach for treatment in neuropathology
(9). For instance, a potent iNOS inhibitor, GW274150, has been
used in phase II clinical trials to treat migraine, and NOS inhibitors
are known to provide neuroprotection in PD (13) or under con-
ditions of cerebral ischemia and cerebral artery occlusions (62, 63).
In various models of neurodegeneration, pharmacological inhibi-
tion of iNOS produced beneficial effects (14, 15) confirming that
reducing nitrergic neurotoxicity can protect the central nervous
system (64). In addition, two NOS blockers, L-NNA and
L-NAME, have been used in human trials to treat septic shock
showing mixed outcomes and thus require further investigations
(for review, see ref. 65).
However, the exact downstream targets of NO and its signal-
ing routes in disease remain elusive despite the identification of
numerous proteins targets. There is growing evidence that high
nitrergic activity in conjunction with enhanced oxidative stress
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Fig. 5. L-NAME treatment mitigates prion protein misfolding and reduces neuronal loss in RML mice. (A) Immunoblotting for prion protein in the hippo-
campus from control mice (NBH), prion-diseased mice (RML), and RML + L-NAME–treated mice at 9 w.p.i. (B) (Left) Immunocytochemistry of hippocampal
regions from NBH, RML, and RML + L-NAME–treated mice (ICSM35+DAPI). (Right) Immunocytochemistry of hippocampal regions from NBH, RML, and RML +
L-NAME–treated mice (NeuN + DAPI). (Scale bar: 50 μm.) (C) Summary of relative numbers of cells positive for PrPSc signals (number of PrP-positive cells/
number of total cells) in the hippocampal CA1 region (Student’s t test). (D) Total number of cells (DAPI) counted in hippocampal CA1 region under indicated
conditions. (E) Total number of neurons (NeuN) counted in hippocampal CA1 region under indicated conditions. Data are presented as mean ± SEM, n = 3
NBH, n = 3 to 5 RML and n = 3 RML + L-NAME–treated mice, one-way ANOVA (A, D, and E), *P < 0.05.
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can directly result in activation of glycation signaling (20, 66, 67),
presenting a positive feedback loop to promote further cellular
stress. Glycation has been detected in AD and CJD in earlier
studies (34, 68); however, disease-related 3-NT signaling has only
recently been proposed to involve glycation signaling in AD (21).
This specific pathway requires the dysregulation of glycolysis via
the 3-NT–mediated suppression of TPI activity which results in
increased cellular levels of DHAP. DHAP spontaneously
decomposes to methylglyoxal, which is a highly reactive α-oxo-al-
dehyde that can modify both proteins and DNA to form AGEs.
Methylglyoxal can be metabolized by the glyoxalase pathway,
which requires the presence of GSH (summary pathway, Fig. 6).
As our data show reductions in neuronal GSH levels and associ-
ated enhanced oxidative stress levels in prion disease (8), we
suggest that this detoxifying pathway might be compromised. The
downstream consequences of increased AGE levels are not fully
understood, but emerging evidence implies that this irreversible
modification renders many proteins inactive and susceptible to
misfolding such as in the case of α-synuclein (25, 26) or Aβ (30)
and further increases oxidative stress due to super oxide dismutase
inhibition (69). In our study, we could show that pharmacological
suppression of NO signaling, predominantly targeting neuro-
inflammatory iNOS generated NO, leads to diminished 3-NT of
TPI and subsequent reduction of AGE formation, as confirmed by
reduced RAGE expression. These preventative effects are asso-
ciated with diminished levels of misfolded prion protein (PrPSc)
and improved neuronal health as measured electrophysiologically
and consistent with higher numbers of pyramidal neurons in the
hippocampus and cortex of L-NAME–treated animals. Since one
mechanism that leads to the stabilization and deposition of PrPSc
fibrils may be the result of specific AGE modifications of PrPSc, it
is possible that inhibition of NO-mediated AGE formation might
be an approach of slowing PrPSc misfolding, thereby alleviating the
progression of prion disease. This could present an approach to
diminish the detrimental neuroinflammatory effects seen in neu-
rodegeneration since our evidence for a prolonged neuronal
health as a result of treatment implicates this signaling route as an
important contributor to neuronal degeneration (Fig. 6) and
highlights nitrergic stress and glycation signaling as putative tar-
gets for disease-modifying treatments. To take this study forward
it will be important to further dissect the identities of AGEs and
downstream RAGE signaling, with particular interest in the pos-
itive feedback loop of AGE formation of misfolding proteins and
the proneuroinflammatory contributions of RAGE signaling.
Data Availability. All study data are included in the article and
SI Appendix.
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